Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gregory Bryson, Emmalena ^a   Bartlett, Elizabeth ^b   Kiupel, Matti ^a   Hayes, Schantel ^a   Yuzbasiyan Gurkan, Vilma ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b 2209 Biomedical and Physical Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BASE PAIRING; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DNA ISOLATION; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE DELETION; GENETIC ASSOCIATION; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DISEASE MODEL; DOG; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; SEX DIFFERENCE;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; DOGS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SEX FACTORS;

EID: 77957913302     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-559     Document Type: Article

References (55)

1. LaRock RG, Ginn PE. Immunohistochemical staining characteristics of canine gastrointestinal stromal tumors. Vet Pathol 1997, 34(4):303-311. 10.1177/030098589703400406, 9240839.
2. Frost D, Lasota J, Miettinen M. Gastrointestinal Stromal Tumors and Leiomyomas in the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of 50 Cases. Vet Pathol 2003, 40:42-54. 10.1354/vp.40-1-42, 12627712.
3. Kumagai K, Uchida K, Miyamoto T, Ushigusa T, Shinohara S, Yamaguchi R, Tateyama S. Three Cases of Canine Gastroinstestinal Stromal Tumors with Multiple Differentiations and c-kit-Expression. J Vet Med Sci 2003, 65(10):119-1122.
4. Del Piero F, Summers BA, Cummings JF, Mandelli G, Blomme EA. Gastrointestinal Stromal Tumors in Equids. Vet Pathol 2001, 38(6):689-697. 10.1354/vp.38-6-689, 11732803.
5. Hafner S, Harmon BG, King T. Gastrointestinal Stromal Tumors of the Equine Cecum. Vet Pathol 2001, 38(2):242-246. 10.1354/vp.38-2-242, 11280386.
6. Miettinen M, El-Rifai W, H L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 2002, 33(5):478-483. 10.1053/hupa.2002.124123, 12094372.
7. Agaimy A, Wunsch PH, Dirnhofer S, Bihl MP, Terracciano LM, Tornillo L. Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions. Am J Surg Pathol 2008, 32(6).
8. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y. Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors. Cancer Res 1999, 59(17):4297-4300.
9. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CDM, Fletcher JA. KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors. Cancer Res 2001, 61(22):8118-8121.
10. Croom K, Perry C. Imatinib Mesylate: In the Treatment of Gastrointestinal Stromal Tumours. Drugs 2003, 63(5):513-522. 10.2165/00003495-200363050-00005, 12600228.
11. Wong NACS, Young R, Malcomson RDG, Nayar AG, Jamieson LA, Save VE, Carey FA, Brewster DH, Han C, Al-Nafussi A. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003, 43(2):118-126. 10.1046/j.1365-2559.2003.01665.x, 12877726.
12. Debiec-Rychter M, Wasag B, Stul M, Hagemeijer A, Sciot R. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004, 202(4):430-438. 10.1002/path.1546, 15095270.
13. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of Activating Mutations in c-KIT's Juxtamembrane Coding Region in Canine Mast Cell Neoplasms. J Invest Dermatol 1999, 112(2):165-170. 10.1046/j.1523-1747.1999.00488.x, 9989791.
14. Hulzinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373(6512):347-349. 10.1038/373347a0, 7530333.
15. Kindblom L, Remotti H, Aldenborg F, Meis-Kindblom J. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152(5):1259-1269. 1858579, 9588894.
16. Steigen SE, Eide TJ. Gastrointestinal stromal tumors (GISTs): a review. APMIS 2009, 117(2):73-86. 10.1111/j.1600-0463.2008.00020.x, 19239429.
17. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987, 6(11):3341-3351. 553789, 2448137.
18. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO Journal 1988, 7(4):1003-1011. 454427, 2456920.
19. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999, 27(4):689-697. 10.1016/S0301-472X(98)00075-7, 10210327.
20. Roskoski R. Signaling by Kit protein-tyrosine kinase-The stem cell factor receptor. Biochem Biophys Res Commun 2005, 337:1-13. 10.1016/j.bbrc.2005.08.055, 16129412.
21. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002, 33(5):484-495. 10.1053/hupa.2002.124124, 12094373.
22. Blechman J, Lev S, Givol D, Yarden Y. Structure-function analyses of the kit receptor for the steel factor. Stem Cells 1993, 11(2):12-21. 10.1002/stem.5530110804, 7691317.
23. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors. Science 1998, 279(5350):577-580. 10.1126/science.279.5350.577, 9438854.
24. Agaimy A, Dirnhofer S, WÜnsch PH, Terracciano LM, Tornillo L, Bihl MP. Multiple Sporadic Gastrointestinal Stromal Tumors (GISTs) of the Proximal Stomach are Caused by Different Somatic KIT Mutations Suggesting a Field Effect. Am J Surg Pathol 2008, 32(10):1553-1559. 10.1097/PAS.0b013e31817587ea, 18724245.
25. Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N, Singer S, Griffith D, Haley A, Town A, Demetri G, Fletcher C, Fletcher J. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710. 10.1126/science.1079666, 12522257.
26. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006, 130(10):1466-1478.
27. Ostrowski J, Polkowski M, Paziewska A, Skrzypczak M, Goryca K, Rubel T, Kokoszynska K, Rutkowski P, Nowecki Z, Dobosz A, Jarosz D, Ruka W, Wyrwicz L. Functional features of gene expression pro les differentiating gastrointestinal stromal tumours according to KIT mutations and expression. BMC Cancer 2009, 9:413. 10.1186/1471-2407-9-413, 2794290, 19943934.
28. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001, 25(7):571-576. 10.1016/S0145-2126(01)00028-5, 11377682.
29. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H, Kitamura Y. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998, 19(4):323-324. 10.1038/1209, 9697690.
30. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 2006, 56:1-9. 10.1111/j.1440-1827.2006.01924.x, 16398673.
31. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, Lenoir G, Bressac-De Paillerets B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004, 126:318-321. 10.1053/j.gastro.2003.10.079, 14699510.
32. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR, Besmer P. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003, 100(11):6706-6711. 10.1073/pnas.1037763100, 164511, 12754375.
33. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR, Ware CB, Woodell J. A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E. Cancer Res 2005, 65(15):6631-6639. 10.1158/0008-5472.CAN-05-0891, 16061643.
34. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the Juxtamembrane Domain of c-KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs. Vet Pathol 2002, 39(5):529-535. 10.1354/vp.39-5-529, 12243462.
35. Webster JD, Kiupel M, Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 2006, 6(85). 1448201, 16579858.
36. Banerjee S, Makdisi W, Weston A, Mitchell S, Campbell D. Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 1995, 18(5):768-770.
37. Jones C, Grahn R, Chien M, Lyons L, London C. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 2004, 16(2):95-100.
38. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell Tumors. Neoplasia 2006, 8(2):104-111. 10.1593/neo.05622, 1578516, 16611403.
39. Tabone S, Théou N, Wozniak A, Saffroy R, Deville L, Julie C, Callard P, Lavergne-Slove A, Debiec-Rychter M, Lemoine A, Emile J. KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 2005, 1741(1-2):165-172.
40. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Ja e DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, deJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cu J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SMJ, Sutter NB, Thomas R, Webber C, Lander ES. Broad Institute Genome Sequencing Platform Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438(7069):803-819. 10.1038/nature04338, 16341006, Broad Institute Genome Sequencing Platform.
41. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG. Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors. J Am Coll Surg 2006, 202(4):623-629. 10.1016/j.jamcollsurg.2006.01.002, 16571433.
42. Bhattacharyya A, Lilley DM. The contrasting structures of mismatched DNA sequences containing looped-out bases (bulges) and multiple mismatches (bubbles). Nucleic Acids Res 1989, 17(17):6821-6840. 10.1093/nar/17.17.6821, 318415, 2780311.
43. Mol C, Dougan D, Schneider T, Skene R, Kraus M, Scheibe D, Snell G, Zou H, Sang B, Wilson K. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004, 279(30):31655-31663. 10.1074/jbc.M403319200, 15123710.
44. Ma Y, Cunningham M, Wang X, Ghosh I, Regan L, Longley B. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999, 274(19):13399-13402. 10.1074/jbc.274.19.13399, 10224103.
45. London CA. Tyrosine Kinase Inhibitors in Veterinary Medicine. Top Companion Anim Med 2009, 24(3):106-112. 10.1053/j.tcam.2009.02.002, 19732728.
46. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009, 9:66-76.
47. Savage D, Antman K. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002, 346(9):683-693. 10.1056/NEJMra013339, 11870247.
48. Hornick J, Fletcher C. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007, 38(5):679-687. 10.1016/j.humpath.2007.03.001, 17437861.
49. Schnadig I, Blanke C. Gastrointestinal stromal tumors: imatinib and beyond. Curr Treat Options Oncol 2006, 7(6):427-437. 10.1007/s11864-006-0018-5, 17032555.
50. Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors. Recent Pat Anticancer Drug Discov 2008, 3(2):88-99. 10.2174/157489208784638749, 18537751.
51. Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib - and then?. Expert Opin Investig Drugs 2009, 18(4):457-468. 10.1517/13543780902806400, 19335275.
52. Gleixner K, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl W, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 2007, 35(10):1510-1521. 10.1016/j.exphem.2007.06.005, 17681669.
53. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008, 22(4):985-988. 10.1111/j.1939-1676.2008.00132.x, 18564222.
54. Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zatelli A, Zini E. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med 2008, 22(4):1001-1007. 10.1111/j.1939-1676.2008.0128.x, 18564225.
55. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. Clin Cancer Res 2009, 15(11):3856-3865. 10.1158/1078-0432.CCR-08-1860, 19470739.